Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$106.39 USD
-1.62 (-1.50%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $106.38 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Zimmer Biomet (ZBH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$132.79 | $155.00 | $99.00 | 22.94% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Zimmer Biomet comes to $132.79. The forecasts range from a low of $99.00 to a high of $155.00. The average price target represents an increase of 24.96% from the last closing price of $106.27.
Analyst Price Targets (24)
Broker Rating
Zimmer Biomet currently has an average brokerage recommendation (ABR) of 2.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms. The current ABR compares to an ABR of 2.48 a month ago based on 27 recommendations.
Of the 27 recommendations deriving the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 25.93% and 7.41% of all recommendations. A month ago, Strong Buy made up 29.63%, while Buy represented 7.41%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 8 | 8 | 7 | 7 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 16 | 15 | 15 | 14 | 14 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.56 | 2.48 | 2.48 | 2.52 | 2.52 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/1/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Hold |
5/31/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
5/30/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/30/2024 | Goldman Sachs | David H Roman | Not Available | Hold |
5/21/2024 | Argus Research Corp. | David A Toung | Not Available | Strong Buy |
5/3/2024 | Truist Securities | Richard Newitter | Hold | Hold |
5/3/2024 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
5/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/2/2024 | Not Identified | Not Identified | Hold | Hold |
5/2/2024 | Needham & Company | Michael Matson | Hold | Hold |
4/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/4/2024 | Evercore Partners | Vijay Kumar | Hold | Hold |
4/3/2024 | Not Identified | Not Identified | Hold | Hold |
4/2/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | Cowen & Co. | Joshua T Jennings | Hold | Hold |
2/28/2024 | Robert W. Baird & Co. | Jeffrey D Johnson | Strong Buy | Strong Buy |
2/23/2024 | Canaccord Genuity | William J Plovanic | Hold | Hold |
1/7/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
11/13/2023 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
11/7/2023 | UBS | Danielle Antalffy | Not Available | Strong Sell |
11/7/2023 | Wells Fargo Securities | Lawrence H Biegelsen | Hold | Hold |
10/21/2023 | Roth Capital Partners | Jason Wittes | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.56 |
ABR (Last week) | 2.48 |
# of Recs in ABR | 27 |
Average Target Price | $132.79 |
LT Growth Rate | 6.90% |
Industry | Medical - Products |
Industry Rank by ABR | 156 of 252 |
Current Quarter EPS Est: | 1.98 |